This trial compared amcenestrant with letrozole at both doses (200 mg and 400 mg) in the neoadjuvant setting for postmenopausal women with operable ER+/HER2- breast cancer, specifically targeting patients with baseline Ki67 levels of 15% or higher. Here, ESR1 is linked to breast carcinoma.